The Institute for Clinical and Economic Review (ICER) will assess the comparative clinical effectiveness and value of erenumab (Amgen/Novartis) for prevention of migraine headaches. The FDA’s decision on whether to approve erenumab is expected in May of 2018.
In addition, ICER will conduct an update to its 2016 report on therapies for plaque psoriasis. ICER plans to review new evidence that has emerged on the previously reviewed therapies, as well as evidence on recently-approved guselkumab (Tremfya, Janssen/Johnson and Johnson) and on tildrakizumab (Sun Pharma), which is currently under review by the FDA with an expected decision in March of 2018.
Both reports will be publicly discussed during a meeting of the California Technology Assessment Forum in June of 2018, where the independent evidence review panel will deliberate and vote on evidence presented in ICER’s reports.
